NR4A1 and breast cancer: Patients with histologically confirmed, hormone receptor- and/or HER2-positive breast cancer who underwent whole-body [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT in the same week for initial staging or follow-up were included.